GENSCRIPT BIO (01548) announced that, effective January 20, 2026, the board of directors of Legend Biotech Corporation ("Legend," an associate of the company whose shares are listed on the Nasdaq Global Select Market in the form of American Depositary Shares) has appointed Mr. Meng Jiange as a director, with an initial term lasting until Legend's 2026 annual general meeting of shareholders.
Mr. Meng Jiange's appointment fills the position on Legend's board previously held by Dr. Zhu Li, who resigned from the role effective on the aforementioned date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments